Skip to main content

The Biomarker Company

SphingoTec develops and markets innovative in vitro diagnostics solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements into routine clinical practice.

Our innovative biomarkers address diagnostically underserved critical care conditions such as sepsis, acute heart failure, acute kidney injury, and cardiogenic shock. 
We are a fully integrated diagnostics company: our innovative biomarkers are commercially available on the point of care platform Nexus IB10. The assay portfolio for near patient testing goes beyond innovation: on the Nexus IB10 platform, clinicians can deploy a wide range of commonly used parameters in acute and critical care settings, making the analyzer a useful addition to intensive care units (ICU), emergency departments (ED), and other near patient settings. 

Integrated diagnostic solutions for unmet medical needs

Rapid Testing

Point of care diagnostics

Nexus IB10 is a point of care analyzer that provides rapid and reliable diagnostic results. Fully automatic and compact, Nexus IB10 is a solution for near patient testing in acute and critical care settings. 

Test portfolio

Biomarker-based diagnostics

The Nexus IB10 test portfolio includes biomarker innovations and established parameters for acute and critical care such as PCT, Troponin, NT-proBNP, D-Dimer, TSH, and others. 

From bench to bedside

Biomarker innovations

The main mortality drivers in intensive care units are diagnostic blind spots. We pave the way for early intervention and personalized medicine in critical care with innovative biomarkers.

 

Latest News

15. December 2022
SphingoTec announces first data on the kidney function biomarker penKid as a promising tool in supporting early initiation and liberation from RRT. Although RRT remains a pivotal measure in treating AKI complications, it is also associated with significant risks and its duration should be restricted to a minimum.
Read more
15. November 2022
Boditech Med Inc. and SphingoTec GmbH have entered into a non-exclusive royalty-bearing license agreement. Under the terms of this agreement, Boditech has obtained the rights to develop and commercialize clinical tests for the kidney function biomarker penKid on its renowned AFIAS and ichroma Point of Care platforms.
Read more
26. August 2022
Four units at the University Hospital Heidelberg and Heidelberg Kidney Center implement Proenkephalin (penKid) in a pilot biomarker-based treatment approach to diagnose AKI faster and monitor it more accurately across departments.
Read more

Events & Expos

05. - 08. October 2023

12:04 - 13:05

Berlin, Germany

The Forum Nephrologie is a scientific, educational, and networking meeting and part of the 15. Jahrestagung der DGfN. The main congress program will kick off with an opening ceremony on Thursday,…

Read more
14. - 16. June 2023

12:00 - 13:01

Berlin, Germany

We are looking forward to participating for the first time in the 54th Joint Annual Meeting of the German Society of Internal Intensive Care and Emergency Medicine (DGIIN) and the Austrian Society of…

Read more
29. March - 01. April 2023

09:33 - 11:34

San Diego, USA

The CRRT conference provides a comprehensive review of advances in clinical care, research, and technology in critical care medicine with a focus on the kidney and renal support techniques. We are…

Read more

Subscribe to our Newsletter

Follow the link below to subscribe to our Newsletter & receive updates on our company and products

Subscribe now

Follow our Journey on Social Media